Table 3.

Performance of NAMPT inhibitor in combination in vivo.

Cancer/Cell Lines	Drug Combinations	Study Result	Refs.
Non-small cell lung cancer A549, H1299	150 mg/kg/day GMX-1777 for 5 days, i.m. + 600 mg/kg/day Pemetrexed for 5 days, i.p.	Decreased tumor volume Increased body weight	[60]
Ewing Sarcoma TC32, TC71	25 mg/kg GNE-618 p.o. + 50 mg/kg Niraparib p.o.	Decreased tumor volume Increased survival	[62]
Neuroendocrine tumor GOT1	100 mg/kg GMX-1778, three weekly doses, p.o. + 7.5 MBq 177Lu-DOTATATE, single dose, i.v.	Decreased tumor volume Increased survival	[70]
Prostate cancer PC3	4 injections 10 mg/kg of APO-866 for 2 days + 4 fractions 3 Gy radiation for 4 days	Delayed tumor growth Increased survival	[71]
Triple-negative breast cancer CAL51	6 mg/kg FK866 + 15 mg/kg Olaparib for 5 days, followed by 2 days of no treatment, maintained upon study completion	Decreased tumor volume Increased body weight	[63]
Ovarian cancer OVCAR-3	10 mg/kg/day FK866, i.p. + 15 mg/kg APCP, i.p., every other two days for 28 days	Reduced NAD, NMN, ATP Increased cancer necrotic area (Ki67+ staining) Increased survival	[72]
Waldenström macroglobulinemia BCMW.1	30 mg/kg/day FK866 for 4 days in a week (with 3 days off), repeated for 3 weeks + 0.5 mg/kg/day Ibrutinib for 5 days, repeated for 3 weeks	Decreased tumor volume Increased survival	[69]
	100 mg/kg/day KPT-9274 for 5 consecutive days/week for 3 weeks + 25 mg/kg Bendamustine, one single dose/week for 2 consecutive weeks	Highly sensitive Increased apoptosis Decreased tumor volume	[64]
Multiple myeloma MM1S	30 mg/kg FK-866 for 4 days repeated weekly for 3 weeks, i.p. + 0.5 mg/kg Bortezomib biweekly for 3 weeks, s.c.	Decreased tumor volume Increased survival	[68]

i.m.: intramuscular; i.p.: intraperitoneal; p.o.: peroral; i.v.: intravenous; s.c.: subcutaneous.